Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2025-04-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
北京安理（上海）律师事务所关于上海美迪西生物医药股份有限公司2025年员工持股计划的法律意见书
Regulatory Filings
2025-04-21 Chinese
美迪西：董事会对独立董事独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange rules. It is a compliance and governance-related disclosure about board members' independence, not a financial report, earnings release, or management discussion. It does not announce voting results, changes in management, or capital structure. The content fits best under governance-related information about board practices and compliance with independence rules. Therefore, the document is classified as Governance Information (CGR). The document length is short but contains substantive governance content, not just an announcement or certification.
2025-04-21 Chinese
美迪西：关于预计2025年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Medicilon Inc. regarding its expected 2025 annual ordinary related party transactions. It details the nature, amounts, and approval procedures of these related party transactions, including board and supervisory committee approvals, independent director opinions, and the fact that no shareholder meeting approval is required. The document is a regulatory announcement about anticipated related party transactions, not a financial report or audit. It does not contain financial statements or detailed financial analysis but rather disclosures about corporate governance and compliance with related party transaction rules. This fits the category of a Regulatory Filing (RNS) as it is a compliance announcement that does not fit into other specific categories like Annual Report, Interim Report, or Capital Update.
2025-04-21 Chinese
美迪西：2024年年度报告
Annual Report Classification · 100% confidence The document is titled "上海美迪西生物医药股份有限公司2024 年年度报告" which translates to "Shanghai Medicilon Inc. 2024 Annual Report." It contains detailed financial data, management discussion and analysis, company governance, risk factors, financial statements, and auditor's report. The document length is substantial (15,000 characters), and it includes comprehensive financial performance data for the fiscal year 2024, including revenue, net profit, cash flow, and other key financial indicators. It also includes management's discussion and analysis, risk disclosures, and auditor's opinion. These characteristics align with the definition of an Annual Report (10-K), which is an official yearly report covering company activity and full financial performance. There is no indication that this is merely an announcement or a certification, but rather the full report itself. Therefore, the correct classification is Annual Report (10-K). FY 2024
2025-04-21 Chinese
美迪西：2024年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and usage of funds raised by Shanghai Medicilon Inc. in 2024, including specifics on the amount raised, usage, storage, and investment of the funds. It references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, and includes auditor and sponsor opinions on the fund usage. The document is titled as a "专项报告" (special report) on the storage and use of raised funds for the year 2024. It is not a general annual report, earnings release, or management discussion, but a focused report on fundraising and capital usage. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length is substantial and contains detailed financial data related to fundraising and capital use, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-04-21 Chinese
美迪西：2025年员工持股计划管理办法
Capital/Financing Update Classification · 95% confidence The document is titled as the "2025 Employee Stock Ownership Plan Management Measures" for Shanghai Medicilon Inc. It details the principles, procedures, management, rights, obligations, asset composition, and termination conditions of an employee stock ownership plan. The content includes legal references, stock purchase prices, lock-up periods, performance assessments, management committee roles, and shareholder rights related to the employee stock ownership plan. This is a detailed regulatory and procedural document about an employee stock ownership plan, which is a form of capital/financing update related to employee equity incentives. It is not an annual report, earnings release, or other financial report. It is not a simple announcement or proxy statement but a comprehensive plan document. Therefore, the best fitting category is Capital/Financing Update (CAP).
2025-04-21 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.